Daxor Raises $9M in Direct Offering to Bolster Working Capital
Event summary
- Daxor Corporation secured $9M via a registered direct offering of 765,958 shares at $11.75 per share.
- Proceeds will be used for general corporate purposes, including working capital.
- The offering is expected to close on January 26, 2026, subject to customary closing conditions.
- Lake Street Capital Markets, LLC acted as the exclusive placement agent.
The big picture
Daxor's $9M direct offering underscores its push to address healthcare's 'silent crisis' of blood volume measurement. The funding comes amid broader industry shifts toward value-based care, where precise diagnostics like Daxor's BVA system can reduce hospital stays and readmissions. The company's ISO certification and U.S.-based manufacturing further position it for accelerated market expansion, though competition and regulatory dynamics remain key variables.
What we're watching
- Capital Deployment
- How Daxor will allocate the $9M to drive market expansion and operational efficiency.
- Market Penetration
- Whether the funding will accelerate adoption of its Blood Volume Analysis diagnostic.
- Execution Risk
- The pace at which Daxor can integrate the proceeds into its growth strategy.
Related topics